Media stories about Pulse Biosciences (NASDAQ:PLSE) have been trending somewhat positive on Tuesday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pulse Biosciences earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.2259406825433 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- Pulse Biosciences, Inc. (PLSE) Facing Active Insider Investor’s Presence in Ownership: GWG Holdings, Inc. (GWGH) – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Baxter International Inc. (BAX) is at $64.38 per share and Pulse Biosciences, Inc. (PLSE) is listed at $22.99 – Stocks Gallery (stocksgallery.com)
- Pulse Biosciences to Host Quarterly Investor Conference Call on November 7, 2017 (finance.yahoo.com)
- Commit To Purchase Pulse Biosciences At $17.50, Earn 17.5% Annualized Using Options – TheStreet.com (thestreet.com)
Pulse Biosciences (PLSE) opened at 23.73 on Tuesday. The firm’s market cap is $340.15 million. The firm’s 50-day moving average price is $19.32 and its 200-day moving average price is $24.89. Pulse Biosciences has a 52-week low of $5.20 and a 52-week high of $39.50.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.com-unik.info/2017/10/31/pulse-biosciences-plse-given-media-impact-score-of-0-19.html.
In other news, major shareholder Robert W. Duggan acquired 277,450 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was purchased at an average price of $23.14 per share, for a total transaction of $6,420,193.00. Following the completion of the acquisition, the insider now directly owns 3,153,234 shares in the company, valued at approximately $72,965,834.76. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Robert W. Duggan acquired 2,000,000 shares of the firm’s stock in a transaction dated Sunday, September 24th. The shares were purchased at an average price of $15.02 per share, with a total value of $30,040,000.00. Following the acquisition, the insider now owns 5,797,612 shares of the company’s stock, valued at $87,080,132.24. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 2,780,959 shares of company stock valued at $44,211,796. Corporate insiders own 6.70% of the company’s stock.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
What are top analysts saying about Pulse Biosciences Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pulse Biosciences Inc and related companies.